-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
Samsung Leads Global DRAM Market as SK Hynix Gains Share
-
South Korea Proposes Fourth Delay of Cryptocurrency Gains Tax to 2029
-
Kakao Details Spinoff Plan to Monetize AI Through KakaoTalk
-
ASIC Fines Mona Museum Owner's Company for Late Financial Report
-
Business Leaders Condemn Productivity Commission Inquiry for Excluding Tax and Labor Issues
-
Business Leaders Criticize Productivity Commission Inquiry Scope
-
Sheikh Hasina Vows Return to Bangladesh Despite Death Sentence
-
SCANDIC FINANCE ने एलेक्स बोडी को समूह का उपाध्यक्ष नियुक्त किया
-
SCANDIC FINANCE แต่งตั้งอเล็กซ์ โบดี เป็นรองประธานกลุ่มบริษัท
-
SCANDIC FINANCE Grubu, Alex Bodi’yi başkan yardımcılığına atadı
-
Alex Bodi wiceprezesem grupy SCANDIC FINANCE
-
Алекс Боди е назначен за вицепрезидент на групата SCANDIC FINANCE
-
Alex Bodi a SCANDIC FINANCE vállalatcsoport új alelnöke
-
Ο Άλεξ Μπόντι νέος αντιπρόεδρος του ομίλου SCANDIC FINANCE
-
Alex Bodi byl jmenován viceprezidentem skupiny SCANDIC FINANCE
-
Alex Bodi utsedd till vicepresident för SCANDIC FINANCE-koncernen
-
تعيين أليكس بودي نائبًا لرئيس مجموعة SCANDIC FINANCE
-
SCANDIC FINANCEグループ、アレックス・ボディ氏を副社長に任命
-
SCANDIC FINANCE 그룹, 알렉스 보디 부사장 선임
-
亞歷克斯・博迪獲任命為 SCANDIC FINANCE 集團副總裁
-
Алекса Боді призначено віцепрезидентом групи SCANDIC FINANCE
-
Алекс Боди назначен вице-президентом группы SCANDIC FINANCE
Coalition of states vows to protect access to abortion pill under Trump review
A coalition of attorneys general across states including New York, Minnesota and Arizona vowed Monday to protect access to mifepristone, the medication used in the majority of abortions in the United States.
The move comes as the Trump administration has reportedly launched a review into the medication's safety, in what many abortion rights' organizations have dubbed a blatant attempt to undermine health care access.
"The decision to reexamine access to this medication was made in response to a scientifically baseless letter and ignores decades of research that prove mifepristone is safe and effective," read the joint statement that included New York's Attorney General Letitia James, who co-led the coalition of 20 officials in the effort.
"Medical decisions should be left between patients, their families, and their providers – and they should be guided by science, not political agendas," the statement continued.
"If access to mifepristone is challenged, we will take action to protect it," it added.
Officials who co-signed the initiative represented Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, Washington state, and the District of Columbia.
Trump's health chief Robert F. Kennedy Jr and FDA Commissioner Marty Makary reportedly delivered a letter to 22 Republican attorneys general saying that the FDA was conducting its own review of the pill.
Proponents of reviewing mifepristone's safety have cited a study -- which was not peer-reviewed and published on a website, not in a scientific journal -- conducted by a conservative think-tank.
The Ethics & Public Policy Center (EPPC) says its priorities include "pushing back against the extreme progressive agenda while building a consensus for conservatives."
The medication has been used for 25 years in the United States. It is the most common method for abortion care and also routinely used for managing early miscarriage.
Mifepristone, which prevents pregnancy progression, and misoprostol, which empties the uterus, are approved to terminate a pregnancy up to 70 days of gestation in the United States.
C.Amaral--PC